By Rishika Sadam

NEW DELHI (Reuters) -India’s Fortis Healthcare plans to open more dedicated obesity clinics across its hospitals to meet surging demand for weight-loss drugs and therapies in the world’s most populous nation, its CEO told Reuters.

The India launch of popular weight-loss drugs such as Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy this year has heightened patient awareness in the nation projected to have the world’s second-largest population of obese people by 2050.

Mounjaro and Wegvoy’s sales doubled in months after launch, earlier this year.

“We are witnessing a sharp rise in patient interest and demand for structured guidance on weight management and newer obesity-related therapies,” Fortis Managing Director and Chief Executive, Ashutosh Raghuvanshi, said in an inter

See Full Page